Evidence map›Paper›PMID 39814766›Full record

ArticleScientific reports2025

A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials.

Congyang Zheng, Jia Liu, Tao Wang, Haiyang Hu, Yuanyuan Chen

Abstract readNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Congyang ZhengCollege of Traditional Chinese Medicine, Shandong Second Medical University, Weifang, China.
Jia LiuCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Tao WangCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Haiyang HuCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Yuanyuan ChenCollege of Traditional Chinese Medicine, Shandong Second Medical University, Weifang, China. cyy941213@163.com.

Funding

the Project of Scientific Research and Innovation Programme of Shandong Second Medical University 2024BKQ040
6 · The paper itself

Abstract

To update the efficacy and safety of different drugs for the treatment of patients with hyperphosphatemia in chronic kidney disease, we conducted a network meta-analysis of 22 therapies for the treatment of uncontrolled hyperphosphatemia in patients with chronic kidney disease (CKD). All randomized controlled trials on hyperphosphatemia published from January 2013 to November 2023 were searched from CNKI, VIP database, Wanfang database, PubMed, Scopus, and Cochrane databases. Meta-analysis was used to evaluate the serum phosphorus, calcium levels, total effective rate and adverse events of patients with chronic kidney disease (CKD). Data collection and quality evaluation were carried out by three evaluators, RevMan (5.5.3) and Stata (1.3.0). A total of 71 RCTs, and 22 treatment strategies were included in this NMA. The results showed that all treatment strategies were effective in improving patients' blood phosphorus levels. Among them, SL + CT, CA + CC, SL and TCM had higher overall efficacy, RT, TCM and SL + CT had lower blood phosphorus levels, SL + CT, SL and NAM had lower blood calcium levels, and OAC, CC, NAM and SL had higher safety. Among them, SL + CT seems to be the most recommended treatment strategy. In addition, multidrug combination strategies usually have a higher efficacy and safety profile.

Indexed as

HyperphosphatemiaRenal Insufficiency, ChronicCalciumHumansPhosphorusRandomized Controlled Trials as TopicTreatment OutcomeCalciumPhosphorusAdverse eventsChronic kidney diseaseHyperphosphatemiaNetwork meta-analysisSerum calciumSerum phosphorus

Identifiers

PMID39814766
PMCPMC11736078

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.